Biotech gainers: Insmed Incorporated (NASDAQ:INSM), Prothena Corporation (NASDAQ:PRTA), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Biota Pharmaceuticals (NASDAQ:BOTA)



Some days before, shares of Insmed Incorporated (NASDAQ:INSM) fell double digits after the company reported data on a 90 patient Phase 2 trial. Insmed Incorporated (NASDAQ:INSM) stock performance was 7.02% in last session and finished the day at $13.41. Traded volume was 1.55million shares in the last session and the average volume of the stock remained 788.23K shares. The beta of the stock remained 0.69. Insmed Incorporated (NASDAQ:INSM) insider ownership is 1.60%.

Citigroup Inc. initiated coverage on shares of Prothena Corp PLC (NASDAQ:PRTA) in a research report released on Wednesday morning,TheFlyOnTheWall.com reports. The firm issued a buy rating on the stock. Prothena Corporation PLC (NASDAQ:PRTA) rose 8.84 percent to $30.55 Thursday on volume of 343,184.00million shares. The intra-day range of the stock was $27.19 to $31.12. Prothena Corporation PLC (NASDAQ:PRTA) has a market capitalization of $669.14million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George F. Tidmarsh acquired 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The stock was purchased at an average cost of $9.53 per share, with a total value of $76,240.00. La Jolla Pharmaceutical Company (NASDAQ:LJPC)’s stock on Apr 17, 2014 reported a increase of 9.63% to the closing price of $10.02. Its fifty two weeks range is $2.75 -$19.50. The total market capitalization recorded $72.72million. The overall volume in the last trading session was 175,679.00million shares. In its share capital, LJPC has 7.26million outstanding shares.

Biota Pharmaceuticals Inc (NASDAQ:BOTA), Phase 2 trial of Laninamivir Octanoate for the treatment of influenza in adults. Inovio Pharmaceuticals: Phase 2 VGX-3100 DNA vaccine delivered by electroporation. Biota Pharmaceuticals Inc (NASDAQ:BOTA), Inovio Pharmaceuticals (INO) and Athersys (ATHX) will all be expecting to report top-line phase 2 data by mid 2014. On Thursday, shares of Biota Pharmaceuticals Inc (NASDAQ:BOTA) advanced 6.01% to close the day at $5.47. Company return on investment (ROI) is -21.20% and its monthly performance is recorded as -11.49%. Biota Pharmaceuticals Inc (NASDAQ:BOTA) quarterly revenue growth is 14.68%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone